4//SEC Filing
Biocon Pharma Inc. 4
Accession 0000950170-24-106877
CIK 0002023658other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:39 PM ET
Size
14.1 KB
Accession
0000950170-24-106877
Insider Transaction Report
Form 4
Biocon Ltd
10% Owner
Transactions
- Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−9,990,144→ 0 total(indirect: By Biocon Pharma Inc.)→ Common Stock (1,080,775 underlying) - Conversion
Common Stock
2024-09-16+1,080,775→ 1,080,775 total(indirect: By Biocon Pharma Inc.) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−40,000,000→ 0 total(indirect: By Biocon Limited)→ Common Stock (4,327,365 underlying) - Conversion
Common Stock
2024-09-16+4,327,365→ 4,443,122 total(indirect: By Biocon Limited)
Biocon Pharma Inc.
10% Owner
Transactions
- Conversion
Common Stock
2024-09-16+4,327,365→ 4,443,122 total(indirect: By Biocon Limited) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−40,000,000→ 0 total(indirect: By Biocon Limited)→ Common Stock (4,327,365 underlying) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−9,990,144→ 0 total(indirect: By Biocon Pharma Inc.)→ Common Stock (1,080,775 underlying) - Conversion
Common Stock
2024-09-16+1,080,775→ 1,080,775 total(indirect: By Biocon Pharma Inc.)
Footnotes (3)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.
- [F2]Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0002036121
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 4:39 PM ET
- Size
- 14.1 KB